CHAPEL HILL, N.C., Apr 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc.
(Nasdaq: POZN), a pharmaceutical development company with a portfolio of product
candidates for the treatment of migraine, today announced its plan to conduct a
conference call following the release of financial results for the first quarter
ended March 31, 2002. The company will release earnings before the market opens
on Thursday, April 25, 2002. John R. Plachetka, Pharm.D., POZEN's chairman,
president and chief executive officer, and Matthew E. Czajkowski, chief
financial officer, will host the conference call the same day at 11:00 a.m.
The conference call will be simulcast live on the Internet, and can be accessed
by logging on to www.ccbn.com . A replay will be available at this site, as well
as on the Investor Relations section of the company's website, www.pozen.com,
for seven days.
North Carolina-based POZEN Inc. is a pharmaceutical development company
committed to building a portfolio of products with significant commercial
potential in select therapeutic areas. POZEN's initial focus is on developing
products for migraine therapy, a global market expected to exceed $2.6 billion
this year. The company's common stock is traded on The Nasdaq Stock Market under
the symbol "POZN."
POZEN is on the Internet at www.pozen.com .
Chief Financial Officer, of POZEN
Kathy Brunson of FRB Weber Shandwick